Compare Fox Corp Class B (FOX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs TG Therapeutics Inc — how do they compare? Fox Corp Class B trades at $55.42 (market cap $24.58B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Fox Corp Class B is far larger — about 3.2× TG Therapeutics Inc's market cap, and Fox Corp Class B pays a 1.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FOX | TGTX | |
|---|---|---|
Market Cap | $24.58B | $7.64B |
Sector | Media | Health |
52-Week High | $67.76 | $59.06 |
52-Week Low | $44.39 | $26.94 |
Enterprise Value | $27.94B | $7.84B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX Corp trades at $55.99, down 0.6% with bullish technical signals and strong fundamental performance. The company reported robust Q2 2026 earnings of $1.79 EPS, beating expectations by 24%, with revenue growth accelerating to $16.3B in 2025. Analyst sentiment remains mixed with 43% buy ratings, while technical indicators show support at $54-55 levels with moving averages trending upward.
Outlook remains positive with digital growth momentum from Tubi and FOX One driving advertising revenue. Key risks include advertising market volatility and competitive pressures. The stock presents value opportunity with reasonable P/E of 14.4x and strong cash flow generation, though investors should monitor Q3 2026 earnings delivery against $2 EPS expectations.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
